About the Authors

Olav Dalgard

odalgard@medisin.uio.no

Affiliations Akershus University Hospital, Lørenskog, Norway, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

Ola Weiland

Affiliation Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

Geir Noraberg

Affiliation Sørlandet sykehus, Arendal, Norway

Lars Karlsen

Affiliation Stavanger University Hospital, Stavanger, Norway

Lars Heggelund

Affiliation Vestre Viken, HF, Drammen, Norway

Martti Färkkilâ

Affiliation Helsinki University Hospital, Helsinki, Finland

Ulla Balslev

Affiliation Copenhagen University Hospital, Herlev, Denmark

Erika Belard

Affiliation Copenhagen University Hospital, Herlev, Denmark

Anne Øvrehus

Affiliation Odense University Hospital, Odense, Denmark

Mette Skalshøi Kjær

Affiliation Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Henrik Krarup

Affiliation Aalborg University Hospital, Aalborg, Denmark

Birgit Thorup Røge

Affiliation Kolding Hospital, Kolding, Denmark

Sofie Hallager

Affiliation Copenhagen University Hospital, Hvidovre, Denmark

Lone G. Madsen

Affiliation Køge Hospital, Køge, Denmark

Alex Lund Laursen

Affiliation Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark

Martin Lagging

Affiliation Sahlgrenska Academy, University of Gothenburg, Gothenborg, Sweden

Nina Weis

Affiliations Copenhagen University Hospital, Hvidovre, Denmark, Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Competing Interests

Olav Dalgard: Research grants Gilead, Abbvie and Merck. Paid lectures Abbvie, Merck and Gilead. Chair of committee writing Norwegian national guidelines for HCV treatment in Norway. Nina Weis: Clinical investigator, speaker and advisory board member for Abbvie, Bristol Myers Squibb and Merck Sharp & Dohme; speaker and advisory board member for Gilead. Lars Karlsen: Advisory boards: Merck, Abbvie, Gilead, Bristol-Myers Squibb. Member of the committee that write national guidelines for HCV treatment in Norway Clinical expert in HCV for The Norwegian Medicines Agency Martti Färkkila: Study grant: Gilead. Speaker and consultation fee, MSD Finland, Janssen, BMS, Takeda, Pfizer, Cook Ireland, Intercept Ola Weiland: Consultancies: AbbVie, BMS, Gilead, Janssen, Medivir, Roche and MSD/Merck. Speaker’s bureau: AbbVie, BMS, Gilead, Janssen, Medivir, Roche and MSD/Merck Lone Madsen: Lecture fees from: BMS and Medivir. Advisory Board member: AbbVie and BMS. Mette Kjær: Speakers fee from Abbvie. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: OD GN NW OW. Data curation: OD. Formal analysis: OD. Funding acquisition: OD. Investigation: OD OW GN LK LH MF UB EB AØ MSK HK BTR SH LGM ALL ML NW. Methodology: OD GN NW OW. Project administration: OD NW. Software: OD. Supervision: OD. Validation: OD. Visualization: OD. Writing – original draft: OD. Writing – review & editing: OD ML NW OW.